# Government-Owned Inventions; Availability for Licensing
**AGENCY:**
National Institutes of Health, HHS.
**ACTION:**
Notice.
**SUMMARY:**
The invention listed below is owned by an agency of the U.S. Government and is available for licensing and/or co-development in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing and/or co-development.
**DATES:**
Only written comments and/or applications for a license which are received by the National Cancer Institute, Technology Transfer Center on or before January 29, 2016 will be considered.
**ADDRESSES:**
Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD, 20850-9702.
**FOR FURTHER INFORMATION CONTACT:**
Information on licensing and co-development research collaborations, and copies of the U.S. patent applications listed below may be obtained by contacting: Attn. Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD, 20850-9702, Tel. 240-276-5515 or email *[email protected]* . A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications.
**SUPPLEMENTARY INFORMATION:**
Technology description follows.
*Title of invention:* A Novel Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treatment of CD30+ Lymphoma.
*Description of Technology:* Chimeric antigen receptors (CARs) are hybrid proteins that consist of two major components: A targeting domain and a signaling domain. The targeting domain allows T cells which express the CAR to selectively recognize and bind to diseased cells that express a particular protein. Once the diseased cell is bound by the targeting domain of the CAR, the signaling domain of the CAR activates the T cell, thereby allowing it to kill the diseased cell. This is a promising new therapeutic approach known as adoptive cell therapy (ACT).
Researchers at the National Cancer Institute's Experimental Transplantation and Immunology Branch developed a CAR that recognizes human tumor necrosis factor receptor superfamily member 8 (TNFRSF8, also known as CD30). The expression of CD30 is deregulated in a variety of human cancers, including many lymphomas. By creating a CAR that recognizes CD30, it may be possible to treat these cancers using adoptive cell therapy.
**Potential Commercial Applications**
—Treatment of human cancers associated with expression of CD30 or variants thereof
—Specific cancers include: Non-Hodgkins Lymphomas, Hodgkin's Lymphomas, several solid malignancies
**Value Proposition**
—Human components are less likely to cause adverse or neutralizing immune response in patients
—Targeted therapies decrease non-specific killing of healthy cells and tissues, resulting in fewer off-target side-effects and healthier patients
**Development Stage**
In vivo/Lead Validation.
**Inventor(s)**
Jim N. Kochenderfer, M.D. (NCI).
**Intellectual Property**
HHS Reference No. E-001-2016/0-US-01
US Provisional Application 62/241,896 (HHS Reference No. E-001-2016/0-US-01) filed October 15, 2015 entitled “A Novel Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treatment of CD30+ Lymphoma”
*Licensing Opportunity:* Researchers at the NCI seek licensees for a chimeric antigen receptor (CAR) that recognizes human tumor necrosis factor receptor superfamily member 8 (TNFRSF8, also known as CD30) for use as a cancer therapeutic.
**Contact Information**
Requests for copies of the patent application or inquiries about licensing and/or research collaboration and co-development opportunities should be sent to John D. Hewes. Ph.D., email: *[email protected]* .
Dated: December 22, 2015.
Thomas M. Stackhouse,
Associate Director, Technology Transfer Center, National Cancer Institute.